中文名称:ANTI-CTLA4抗体英文名称:Anti-CTLA4 antibody 产品类别:抗体 抗体名:Anti-human CD152 靶点:Human CD152(CTLA-4) 浓度: 1mg/ml 应用范围:WB, ELISA 适应物种:Human 克隆性:多克隆: 保存条件: .Store at -20*C,Avoid freeze 1 thaw cycle. ...
抗CTLA 4抗体(16-66)英文名字 Anti-CTLA4 antibody (16-66) 供应商 Nordic BioSite 产品货号 NDC-ASJ-OMYMZM-200 产品报价 ￥询价/200ul 产品说明书 点击查看 购买方式 90%产品中国有现货库存。银行转账、电汇、支票、现金,在线支付宝及网银支付,或直接与我们电话联系400-6800-868...
抗CTLA 4抗体(49-223)英文名字 Anti-CTLA4 antibody (49-223) 供应商 Nordic BioSite 产品货号 NDC-ASJ-7PA8TA-200 产品报价 ￥询价/200ul 产品说明书 点击查看 购买方式 90%产品中国有现货库存。银行转账、电汇、支票、现金,在线支付宝及网银支付,或直接与我们电话联系400-6800-868...
Anti-CTLA4 antibody 英文别名: ANTI-CD152;ANTI-CTLA-4;ANTI-PIG CTLA-4;ANTI-HUMAN CD152;ANTI-HUMAN CTLA-4;Anti-CTLA4 antibody;ANTI-CD152, HUMAN (MOUSE);ANTI-HUMAN CTLA-4 EXTRACELLULAR DOMAIN;Anti-Cytotoxic T-lymphocyte-associated Molecule-4;Monoclonal Anti-CD152 antibody produced in mouse ...
Anti CTLA-4 antibodyDisclosed are anti-CTLA-4 antibodies. Also disclosed are compositions comprising such antibodies, as well as uses of such antibodies and methods of using such antibodies.ワン,チェン-イゴー,イヴヨー,ショクピン
中文名称:Anti-CTLA4;细胞毒性T细胞抗原-4抗体 英文名称:Anti-CTLA4 产品别名:CD 152; CD152; CD152 antigen; Celiac disease 3; CELIAC3; CTLA 4; CTLA-4; Cytotoxic T cell associated 4; Cytotoxic T lymphocyte associated 4; Cytotoxic T lymphocyte associated antigen 4 ...
产品名称Nurulimab (anti-CTLA-4) 别名诺瑞利单抗 | 诺瑞利单抗 英文别名ALPS5 antibody | CD 152 antibody | CD antibody | CD152 antibody | CD152 antigen antibody | CD152 isoform antibody | Celiac disease 3 antibody | CELIAC3 antibody | CTLA 4 antibody | CTLA-4 antibody | CTLA4 antibody |...
产品名称Tremelimumab (anti-CTLA-4), 细胞毒性 T 淋巴细胞相关蛋白 4 (CD152) 抗体 别名曲美木单抗 英文别名Tremelimumab | Ticilimumab | CP-675 | 206 | ALPS5 antibody | CD 152 antibody | CD antibody | CD152 antibody | CD152 antigen antibody | CD152 isoform antibody | Celiac disease 3 anti...
Quavonlimab(Anti-CTLA-4 / CD152)是一种针对细胞毒性 T 淋巴细胞相关抗原 4 (CTLA-4) 的单克隆抗体。它在晚期非小细胞肺癌的一线治疗中显示出疗效。分子量:144.24KD。 规格价格库存购买数量 1mg3490现货 1mg*513841.1现货 1mg*2541523.3现货 更大包装有超大折扣 ...
Harbour BioMed announced that the abstract detailing clinical data from its Australian phase I study of next-generation anti-CTLA-4 antibody in patients with advanced solid tumors will be presented as an e-poster at the 2021 European Society for Medical